GHRS - GH Research PLC News

Guggenheim Maintains Buy on GH Research, Raises Price Target to $40

Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the pr

Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40

Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight an

Needham Maintains Buy on GH Research, Raises Price Target to $39

Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price tar

GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate

GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst cons

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001

Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44

Wells Fargo analyst Benjamin Burnett initiates coverage on GH Research (NASDAQ:GHRS) with a Overw

Why Is GH Research Stock Trading Higher on Thursday?

GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher

Why Is GH Research Stock Trading Higher on Thursday?

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session

CleanSpark shares surge after company secures $6.6B data center lease agreement

CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease

Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capa

Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the

GH Research Announces Publication Of Full Results From Its Phase 2a Trial In Postpartum Depression

GH Research PLC (NASDAQ:GHRS) today announced the publication of the full results from its Phase 2a

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publica

seekingalpha.com

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression.

HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $65

HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Bu

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets

Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $35

Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight an

Citizens Maintains Market Outperform on GH Research, Lowers Price Target to $39

Citizens analyst Jason N. Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and

Earnings Scheduled For May 14, 2026

GH Research Q1 EPS $(0.31) Misses $(0.28) Estimate

GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.31) per share which missed the analyst co

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses s

'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants'

Health officials explored restricting specific antidepressants among SSRI drugs-sources

GH Research Prices ~$117.5M Offering Of 6.528M Shares At $18/Share

GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming

GH Research Announces Pricing of $117.5 Million Underwritten Offering

DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharm

FTSE 100 Live: London stocks slide as aerospace and defence sector falls

FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developme

12 Health Care Stocks Moving In Monday's After-Market Session

Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monda

Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainer

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental

DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharm

feeds.benzinga.com

Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Goin

Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump

Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Goin

Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump

Psychedelics stocks rise after Trump order expands research, access pathways

Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Tru

Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1

defenseworld.net

Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS)

Prenetics Global (NASDAQ: PRE - Get Free Report) and GH Research (NASDAQ: GHRS - Get Free Report) ar

'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Mariju

https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-t

GH Research Announces Two-Peer Reviewed Publications From Its Phase 2B Clinical Program Of GH001 For

GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and

DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharm

seekingalpha.com

GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3

GH Research PLC remains well-capitalized with $280.7 million in cash, supporting its lead candidate

Citizens Maintains Market Outperform on GH Research, Raises Price Target to $42

Citizens analyst Jason N. Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and

Needham Maintains Buy on GH Research, Raises Price Target to $32

Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price tar

GH Research Q4 EPS $(0.23) Beats $(0.28) Estimate

GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst cons

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP co

HC Wainwright & Co. Maintains Buy on GH Research, Raises Price Target to $70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Bu

RBC Capital Maintains Outperform on GH Research, Raises Price Target to $40

RBC Capital analyst Brian Abrahams maintains GH Research (NASDAQ:GHRS) with a Outperform and rais

Canaccord Genuity Maintains Buy on GH Research, Raises Price Target to $39

Canaccord Genuity analyst Sumant Kulkarni maintains GH Research (NASDAQ:GHRS) with a Buy and rais

Needham Maintains Buy on GH Research, Raises Price Target to $29

Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price tar

Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday